Genmab A (GMAB) Non-Current Deferred Tax Liability (2024 - 2026)
Genmab A's (GMAB) quarterly Non-Current Deferred Tax Liability came in at $365.0 million in Q1 2026, up 10.61% YoY from $330.0 million in Q1 2025, and little changed on a QoQ basis from $364.0 million in Q4 2025.
Genmab A (GMAB) Non-Current Deferred Tax Liability (2024 - 2026) Analysis & Trends
Genmab A (GMAB) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $365.0 million in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability rose 10.61% year-over-year to $365.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $365.0 million (up 10.61% YoY) and the FY2025 annual result came in at $364.0 million, up 10.3% from the prior year.
- Non-Current Deferred Tax Liability held at $365.0 million in Q1 2026, from $364.0 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $365.0 million in Q1 2026 to a low of $330.0 million in Q4 2024.
- A 3-year average of $341.5 million and a median of $330.0 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2025 — Non-Current Deferred Tax Liability increased 10.3% — and 2026, when it advanced 10.61%.
- Tracing GMAB's Non-Current Deferred Tax Liability over 3 years: stood at $330.0 million in 2024, then advanced by 10.3% to $364.0 million in 2025, then grew by 0.27% to $365.0 million in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $365.0 million (Q1 2026), $364.0 million (Q4 2025), and $330.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 364.00 Mn |
| Jun 30, 2026 | 364.00 Mn |
| Mar 31, 2026 | 365.00 Mn |
| Mar 31, 2026 | 365.00 Mn |
| Dec 31, 2025 | 364.00 Mn |
| Dec 31, 2025 | 364.00 Mn |
| Sep 30, 2025 | 330.00 Mn |
| Sep 30, 2025 | 330.00 Mn |
| Jun 30, 2025 | 330.00 Mn |
| Jun 30, 2025 | 330.00 Mn |
| Mar 31, 2025 | 330.00 Mn |
| Mar 31, 2025 | 330.00 Mn |
| Dec 31, 2024 | 330.00 Mn |
| Dec 31, 2024 | 330.00 Mn |